Intravenous Immunoglobulin in the Treatment of Adalimumab-associated Optic Neuritis
| Autor: | Naohiro Uchio, Toshiyuki Takahashi, Daiki Yashita, Akihito Hao, Hideyuki Matsumoto |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Optic Neuritis Visual acuity genetic structures Gastroenterology Myelin oligodendrocyte glycoprotein Internal medicine Internal Medicine Adalimumab Humans Medicine Optic neuritis Autoantibodies Aquaporin 4 biology business.industry Autoantibody Immunoglobulins Intravenous General Medicine Middle Aged medicine.disease biology.protein Female Myelin-Oligodendrocyte Glycoprotein Tumor necrosis factor alpha Antibody medicine.symptom business Complication medicine.drug |
| Zdroj: | Internal Medicine. 61:429-432 |
| ISSN: | 1349-7235 0918-2918 |
| Popis: | Optic neuritis (ON) is a rare complication of tumor necrosis factor (TNF)-α inhibitors. The autoantibody serostatus, treatment, and outcome of TNF-α inhibitor-associated ON remain unclear. We herein report a 50-year-old woman with ON following adalimumab therapy. The patient presented with decreasing visual acuity of the right eye, quickly diminishing to light perception. Anti-aquaporin-4 (anti-AQP4) and anti-myelin oligodendrocyte glycoprotein antibodies were negative. Adalimumab was discontinued, and intravenous methylprednisolone and intravenous immunoglobulin (IVIg) were administered. However, her visual acuity improved only up to counting fingers. IVIg may be ineffective depending on the pretreatment severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|